Staten Biotechnology B.V. aims to develop novel and innovative strategies for the treatment of dyslipidaemia, with a focus on hypertriglyceridemia treatment. BioGeneration Ventures (BGV) provided the company's seed financing in 2014 and Forbion led the Series A round, as the sole new investor. Staten is a prime example of Forbion's and BGV's company building activities, growing great scientific ideas into promising companies.
| Website | http://www.statenbiotech.com |
| Revenue | $5 million |
| Employees | View employees |
| Founded | 2014 |
| Address | 5j Transistorweg, Nijmegen, Gelderland, NL |
| Phone | +31 35 760 6500 |
| Industry | Biotechnology, Business Services General, Business Services, Science and Engineering, Drug Discovery, Therapeutics, Health Care |
| Competitors | Roche, Novartis, Pfizer, AstraZeneca, Amgen, Regeneron, Gilead Sciences, Vertex Pharmaceuticals, Illumina, Moderna Therapeutics +44 more (view full list) |
| SIC | SIC Code 873 Companies, SIC Code 87 Companies |
| NAICS | NAICS Code 5417 Companies, NAICS Code 54 Companies, NAICS Code 541 Companies, NAICS Code 541713 Companies, NAICS Code 54171 Companies |
Looking for a particular Staten Biotechnology employee's phone or email?
Staten Biotechnology Questions
The Staten Biotechnology annual revenue was $5 million in 2026.
Staten Biotechnology is based in Nijmegen, Gelderland.
The NAICS codes for Staten Biotechnology are [5417, 54, 541, 541713, 54171].
The SIC codes for Staten Biotechnology are [873, 87].
